Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | Innovations in treatment options for patients with BCG-unresponsive urothelial carcinoma

Petros Grivas • 20 Oct 2023
ESMO 2023
Genitourinary Cancer Urothelial Carcinoma Erdafitinib

Petros Grivas, MD, PhD, University of Washington School of Medicine, Seattle, WA discusses the recent advancements in the field of treating advanced, BCG-unresponsive urothelial carcinoma. Dr Grivas elaborates on the development of TAR-200 and its implication in the administration of erdafitinib.This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Petros Grivas

1:08
Phase III clinical trials exploring targeted combination therapies for patients with UC
Petros Grivas • 20 Oct 2023
1:39
Phase Ib trial of bintrafusp alfa for advanced urothelial cancer
Petros Grivas • 20 Oct 2023
2:21
How junior physicians can develop a successful career in medical oncology
Petros Grivas • 20 Oct 2023
1:34
PATRIOT II: 1L maintenance avelumab in advanced UC
Petros Grivas • 19 Feb 2022

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals